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AbstrACt
Introduction  To improve maternal and fetal outcomes 
among patients with obstructed labour (OL) in low-
resource settings, the associated electrolyte and metabolic 
derangements must be adequately corrected. Oral 
fluid intake during labour and preoperative intravenous 
fluid replacement following OL corrects the associated 
dehydration and electrolyte changes, but it does not 
completely reverse the metabolic acidosis, that is, a cause 
of intrapartum birth asphyxia and a risk factor for primary 
postpartum haemorrhage due to uterine atony. Sodium 
bicarbonate is a safe, effective, cheap and readily available 
acid buffer, that is, widely used by sportspeople to improve 
performance. It also appears to improve fetal and maternal 
outcomes in abnormally progressing labour. However, its 
effects on maternal and fetal outcomes among patients 
with OL is unknown. We aim at establishing the effect of a 
single-dose preoperative infusion of sodium bicarbonate 
on maternal and fetal lactate levels and clinical outcomes 
among patients with OL.
Methods and analysis  This will be a double blind, 
randomised controlled clinical phase IIb trial. We will 
randomise 478 patients with OL to receive either 50 mL 
of placebo with standard preoperative infusion of normal 
saline (1.5 L) or 4.2 g of sodium bicarbonate solution 
(50 mL of 50 mmol/L) with the preoperative infusion 
of normal saline (1.5 L). The primary outcome will be 
mean lactate levels in maternal capillary blood at 1 hour 
after study drug administration and in the arterial cord 
blood at birth. We will use the intention-to-treat analysis 
approach. Secondary outcomes will include safety, 
maternal and fetal morbidity and mortality up to 14 days 
postpartum.
Ethics and dissemination Makerere University School 
of Medicine Research and Ethics Committee and Uganda 
National Council for Science and Technology have 
approved the protocol. Each participant will give informed 
consent at enrollment.
trial registration number  PACTR201805003364421 
IntroduCtIon
Globally, the annual number of maternal 
deaths (MDs) has decreased from 532 000 in 
1990 to 303 000 in 2015.1 2 But almost all of 
them (99.6%) occur in sub-Saharan Africa 
(66.3%) and South Central Asia,1 where it 
is estimated that the lifetime risk of MD is 
as high as 1 in 16 and 1 in 46, respectively, 
compared with 1 in 2800 in developed 
regions.1 2 Although primary postpartum 
haemorrhage (PPH) and sepsis are the 
leading causes of MD, obstructed labour 
(OL) indirectly contributes to >70% of these 
deaths.3 Directly, OL causes 8% of all the 
MD4 5 and up to 90% of the perinatal deaths 
strengths and limitations of this study
 ► This is among the first studies to investigate the 
effect of preoperative bicarbonate infusion on ma-
ternal and fetal outcomes among patients with 
obstructed labour (OL), using a randomised control 
design.
 ► Measurement of maternal lactate levels and fetal 
cord blood lactate at the bedside using a hand-held 
device (Lactate Pro2), instead of a blood gas analy-
ser, that is, expensive to acquire and operate; in a 
resource-limited setting.
 ► This study will only ascertain the efficacy and not 
the effectiveness of the preoperative sodium bicar-
bonate infusion.
 ► Given the short duration of follow-up, we will not 
have any information regarding the long-term ef-
fects of sodium bicarbonate on maternal and peri-
natal outcomes.
 ► Improving maternal and fetal lactate levels may 
not improve the fetal outcome in OL, as the toco-
lytic effect of the lactate may be a fetal protective 
mechanism.
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due to birth asphyxia.6 In the 2015/2016 financial year, of 
the 246 MDs reported to the Uganda Ministry of Health 
(MOH), 9% were due to OL, 39% were due to haemor-
rhage and 20% were due to sepsis.7 In addition, 69.3% of 
411 perinatal deaths were due to birth asphyxia, although 
the contribution of OL was not specified.
The prevalence of OL varies from 2% to 8% worldwide. 
It is highest in low and middle-income countries (LMICs) 
and is almost non-existent in developed countries.4 5 In 
LMICs, many patients experience delays in accessing 
quality emergency obstetric and neonatal care services, 
so they end up with neglected OL which causes signifi-
cant maternal morbidity (dehydration, uterine rupture, 
sepsis, vesicovaginal/rectovaginal fistulae and postpartum 
haemorrhage) and neonatal morbidity (asphyxia and 
sepsis).3 8 OL occurs when the fetal presenting part does 
not descend into the maternal pelvis despite adequate 
uterine contractions.4 Usually, the obstruction can only be 
safely relieved by an operative delivery.6 In fact, OL is the 
most common indication for primary caesarean section 
and a major risk factor for infective morbidity (puerperal 
and neonatal sepsis) especially in LMICs.3 9
OL is associated with higher levels of lactate in blood 
and amniotic fluid compared with normal labour, and 
this correlates directly with perinatal outcomes.10 Lactate 
is a byproduct of anaerobic respiration, that is, produced 
by both the fetus and the myometrium in response to 
intermittent hypoxia during labour.11 In OL, the episodes 
of hypoxia are prolonged leading to accumulation of 
lactic acid (metabolic acidosis) from anaerobic break 
down of glucose. Although impaired uterine contrac-
tility caused by myometrial acidosis increases the risk 
of primary PPH, it is beneficial to the fetus because it 
increases fetal placental circulation (oxygenation) which 
is protective against intrapartum birth asphyxia.10 12 The 
transfer of excess hydrogen ions across the placenta to 
the fetus is associated with low fetal pH, fetal distress and 
poor APGAR.13
Oral bicarbonate is a widely used acid buffer in sports 
science, to improve physical performance in vigorous 
exercises because it can reverse lactic acidosis.14 Bicar-
bonate does not cross the placental barrier,15 but it plays 
a key role in regulating the maternal and fetal acid–base 
chemistry.13 There are conflicting reports regarding its 
benefits in labour. Earlier studies involving the use of 
bicarbonate in normal labour showed improvements 
in pH, base excess and plasma bicarbonate, but none 
reported APGAR scores. A recent RCT involving the use of 
oral bicarbonate solution in abnormal (dystocic) labour 
reported a significant improvement in both maternal 
and perinatal outcomes.14 Significantly, none of these 
studies reported adverse maternal and perinatal effects 
or included participants with OL. Currently, preoperative 
intravenous infusion with at least 1.5 L of fluid is recom-
mended as a key element of the standard care. This is 
adequate to correct the dehydration and electrolyte 
imbalance but it probably does not completely reverse 
the associated metabolic acidosis.16 17
Various formulations and doses of sodium bicarbonate 
have been safely used for both clinical indications and 
research purposes with no reported adverse clinical reac-
tions. A single preoperative infusion of 4.2 g of sodium bicar-
bonate solution (50 mL of 50 mmol/L) will be given as a 
single dose at enrolment, since OL is an obstetric emergency 
that requires urgent intervention.18 The same dose was used 
orally in the recent trial in which bicarbonate solution was 
administered to women with dystocia in labour.14 The main 
outcome of this study will be to assess whether bicarbonate 
changes the maternal and fetal lactate levels among patients 
with OL. Lactate is easier to measure than full blood gas anal-
ysis using maintenance free, battery operated pocket size 
devices like the Lactate Pro2 (Arkray Factory, Shiga, Japan). 
This device produces accurate results in a short time with a 
high intraclass correlation coefficient which is comparable 
to that of gold standard in a given population, that is, 0.90 
versus 0.92.18 Lactate is comparable to pH and base deficit 
with respect to sensitivity, specificity and predictive values of 
various perinatal complications.13
We hypothesise that supplementation with preop-
erative sodium bicarbonate infusion as an acid buffer 
among patients with OL can reduce maternal acidosis at 
1 hour after administration, while their newborns in the 
bicarbonate group will have less acidosis in cord blood 
at birth. Bicarbonate is safe, effective, cheap and already 
widely used.19 Establishing its effect on maternal and fetal 
outcomes following OL is necessary, because it could 
be added to the standard preoperative care package as 
a form of tertiary prevention. This study aims to estab-
lish the effect of a single-dose preoperative infusion of 
sodium bicarbonate on maternal and fetal lactate levels 
and clinical outcomes among patients with OL.
MEthods/dEsIgn
study design
This will be a superiority, double blind, randomised 
controlled clinical phase IIb trial. Half of the 478 patients 
with OL will receive the intervention (sodium bicarbonate 
infusion) with preoperative normal saline infusion, and 
the other half will receive the standard of care (preopera-
tive saline infusion) alone.
study setting
We will conduct this study in Mbale Regional Referral 
Hospital located at the heart of Mbale Municipality, 
214 km to the East of the capital city, Kampala. It is the 
main referral hospital, serving 14 districts in the Elgon 
zone, bordering western Kenya. This is a government 
run, not-for-profit, charge-free, 470-bed hospital with 
52 maternity beds. The Department of Obstetrics and 
Gynaecology has one consultant, two specialists, three 
medical officers and 21 Midwives. In terms of outputs, the 
labour and delivery suite is only second to the Mulago 
National Referral Hospital labour suite. Annually, about 
12 000 childbirths occur in this hospital with a caesarean 
section rate of 35% and ~500 mothers have OL. The MOH 
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has ranked it as the best performing Regional Referral 
Hospital in Uganda for the last 4 years.
Participants
This study will be carried out among patients with OL 
admitted to the labour suite in Mbale Regional Referral 
Hospital for emergency caesarean section during the 
period of the study. Either a medical officer or specialist 
on duty using the ACOG definition will make the diag-
nosis of OL. In the first stage of labour, she should have 
cervical dilatation >6 cm with ruptured membranes, 
adequate contractions lasting >4 hours with no change 
in cervical dilatation or delay in the second active stage 
of labour (nullipara >2 hours, multipara >1 hour) with 
adequate uterine contractions. In addition, any two of: 
the obvious signs of severe obstruction such as caput 
formation, severe moulding, Bandl’s ring, subconjunc-
tival haemorrhages or an oedematous vulva.
We will include patients with OL carrying singleton, term 
pregnancies (≥37 weeks of gestation) in cephalic presen-
tation. We will exclude patients with other obstetric emer-
gencies such as antepartum haemorrhage, preeclampsia 
and eclampsia (defined as elevated blood pressure of at 
least 140/90 mm Hg, urine protein of at least 2+, any of the 
danger signs and fits), premature rupture of membranes 
and intrauterine fetal death. Patients with comorbidities 
such as diabetes mellitus, sickle cell disease, renal disease, 
liver disease and heart disease. We will also exclude those 
patients with hypokalemia (<3.3 mmol/L), hypocal-
caemia (<8.2 mmol/L), hypernatraemia (>148 mmol/L) 
and alkalosis (bicarbonate >22 mmol/L) because they are 
more likely to develop adverse drug reactions.
randomisation
An independent biostatician will generate a sequence 
of random numbers using the online randomisation 
service of www. sealedenvelope. com in permuted block 
sizes of four, six and eight. Based on this sequence, OL 
patients will be randomly allocated to either interven-
tion or control arms in a 1:1 ratio. An independent phar-
macist who is not involved in the recruitment of study 
participants, will conceal the randomisation sequence 
by preparing new labels with sequential numbers to be 
placed on identical study drug packages each containing 
five similar 10 mL glass vials without the original labels. 
After consent for inclusion is confirmed, a study nurse 
will take the next study drug package and administer its 
contents to the participant.
Intervention
The intervention will be a preoperative infusion of 50 mL 
of sodium bicarbonate 8.4% solution equivalent to 4.2 g or 
50 mmol/L of bicarbonate (Martindale Pharma, Essex, UK) 
in 10 mL glass vials. The sodium bicarbonate will be admin-
istered intravenously as a bolus immediately after recruit-
ment by trained research assistants who are all experienced 
midwives working in the labour suite, followed by 1.5 L of 
normal Ssline over the next hour.
Comparator
Participants in the control arm will receive a preoperative 
infusion of normal saline, which is part of the current stan-
dard of care. Fifty millilitres of sodium chloride 0.9% in iden-
tical 10 mL glass vials (AccuHealth Care, Gujarat, India) will 
be administered intravenously as a bolus immediately after 
recruitment by trained research assistants, who are all expe-
rienced midwives working in the labour suite, followed by 
1.5 L normal saline over the next hour.
In addition, recruits will receive the standard preoper-
ative care which includes preoperative antibiotic prophy-
laxis, at least 1.5 L of intravenous fluids preoperatively, 
bladder emptying, administration of oxygen and lying in 
left-lateral position.16
Measurements
The primary outcomes in this study will be the mean lactate 
levels in maternal capillary blood at 1 hour after the onset of 
study drug administration and in arterial cord blood within 
1 min of birth. We will measure lactate at the bedside using a 
hand-held Lactate Pro2 device (Arkray Factory).
The secondary maternal outcomes will include 
myometrial lactate levels at caesarean section, maternal 
mortality up to 14 days postpartum. Other morbidi-
ties such as primary PPH, birth canal injuries, duration 
of admission, puerperal sepsis (persistent fever >38°C, 
chills and general malaise, pain in the lower abdomen, 
persistent bloody/pus discharge [lochia] from genital 
tract, which may have an unpleasant smell, tenderness 
on palpating the uterus uterine subinvolution, wound 
dehiscence/burst abdomen),16 fistulae and readmis-
sions. Secondary perinatal outcomes will include mean 
lactate in venous cord blood, APGAR score, admission to 
the NICU, asphyxia, neonatal sepsis (irritability, poorly 
breast feeding, bulging anterior fontanelle)16 and peri-
natal death up to 7 days postpartum.
For the secondary safety outcomes, we will monitor for 
the following drug reactions throughout the period of the 
study. Frequent urge to urinate, continuing headache, 
continuing loss of appetite, mood or mental changes, 
muscle pain or twitching, nausea or vomiting, stomach 
crumps, slow breathing, swelling of feet or lower limbs, 
unpleasant taste, increased thirst, unusual tiredness or 
weakness, venous irritation, cellulitis and intravenous site 
pain.20–22
sociodemographic, clinical and laboratory characteristics
Using an interviewer administered questionnaire and 
available records (antenatal cards, facility registers and 
case report files), sociodemographic and clinical char-
acteristics will be collected by trained research assistants. 
At baseline, five millilitres of blood will be collected in 
the appropriate vacutainers for a complete blood count, 
renal function tests, liver function tests and electro-
lytes. Ten millilitres of fresh urine will be collected in a 
sterile container for analysis. All these specimens will be 
delivered to MBN clinical laboratories within 1 hour of 
collection for analysis. Figure 1 shows the Consolidated 
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Standards of Reporting Trials flow diagram for this study. 
We will follow-up patients for up to 14 days postpartum 
either by phone call if they are discharged or by direct 
visits if they are still admitted according to the current 
standard of care for patients with OL in Uganda.
sample size and power calculation
Since the multiple testing in this study will be corrected 
for at analysis, we estimated the sample size to cater for 
that. The testing will take place c = two times, the final 
analysis will use a Bonferroni-Holm correction to adjust 
for multiplicity and the critical value will divide the α level 
by c.
To detect a Δ=15% difference in mean lactate levels 
between the intervention and control arms. Assuming an 
equal number of participants in each group, a two-sided 
significance level α of 0.05 for a 95% CI, a power (1−β) 
of 90%, an allowance of c = two multiple comparisons 
and a Bonferroni-Holm method for comparison of 
means, we used the formula,  n >=
(
Z1−α2c + Z1−β
)2
2
( SD
∆
)2
 
23 and Open Epi24 to determine the sample size. Where 
 Z1−
α
2c
= Z1− 0.052∗2
= Z1−0.0125 = 2.24 
 and  Z1−β = Z1−0.1 = Z0.9 = 1.28  
using standard normal tables.
The mean and SD of the maternal venous lactate at 
the end of second stage of labour is 2.6±1.0 mmol/L25 
Figure 1 Flow diagram of study participants in the trial.
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without any use of bicarbonate. To detect a difference 
of 15% (0.39 mmol/L) at 1 hour and assuming the same 
SD of ±1 in both arms, 326 participants will be required. 
Correcting for an attrition rate of 10%,14 gives a total 
sample size of 364.
The mean arterial umbilical cord blood lactate at 37 
weeks of gestation is 4.3±1.9 mmol/L26 without any use 
of bicarbonate. In order to detect a difference of 15% 
(0.645 mmol/L) at birth and assuming the same SD 
of ±1.9 in both groups, 432 participants will be recruited. 
Correcting for an attrition rate of 10%14 gives a total 
sample size of 478. We therefore chose a sample size of 
478 to provide adequate power for both hypotheses.
data collection and management
Well-trained RAs will collect data using a pretested inter-
viewer administered electronic questionnaire on pass-
word protected smart phones using the Open Data Kit 
software.27 To increase accuracy, the data will be triangu-
lated with a review of relevant health facility records such 
as the antenatal cards, the maternity and theatre registers 
and the participants’ case notes. The questionnaire will be 
coded with checks for internal consistency. Data on socio-
demographic, clinical and laboratory parameters will be 
collected at baseline, at 1 hour after onset of study drug 
administration for the primary maternal outcome, at the 
time of childbirth for the primary neonatal outcome and 
at 7 and 14 days postpartum for the secondary perinatal 
and maternal outcomes as summarised in table 1. The PI 
will review the entries from the Google aggregate server 
every 24 hours to ensure data quality and completeness.
statistical analysis
This will be conducted using STATA V.14 software or 
higher using the principle of ‘intention to treat’. Descrip-
tive statistics will be used to summarise baseline character-
istics of the study participants and assess if randomisation 
was successful. The primary maternal outcome will be 
the difference in capillary blood lactate levels at 1 hour 
after onset of study drug administration. The Bonfer-
roni-Holm method28 29 will be used to compare the differ-
ence in means at baseline and 1 hour after onset of study 
drug administration both within and between each of the 
two arms.
For the primary fetal outcome of mean arterial cord 
blood lactate at birth, the Bonferroni-Holm method will 
be used to compare the mean lactate levels in the two 
arms within 1 min of childbirth.
The secondary outcomes will be reported as propor-
tions in each of the two arms. Categorical variables will be 
compared using the χ2 and Fisher's exact tests. Potential 
confounders and effect modifiers unbalanced at baseline 
and associated with the outcome (p<0.05) will be adjusted 
for using multivariable linear or/and logistic regression. 
Proportions and the number needed to treat/number 
needed to harm will be reported for the secondary 
maternal and fetal outcomes.
We will do a subgroup analysis of patients admitted as 
referrals with a diagnosis of OL (to represent patients most 
likely to have neglected OL) to compare them with those 
who are diagnosed with OL within the referral hospital. A 
second subgroup analysis will be for those patients who give 
birth >2 hours after administration of the study drug, when 
we expect the effect of the intervention to have worn off.
Quality control
We will conduct a dry run for a period of 1 month before 
introducing the intervention. To facilitate the training 
of all the research assistants in the study protocol proce-
dures, filling of study questionnaires using the ODK soft-
ware,27 accurate measurement of lactate at the bedside 
using the Lactate Pro2 device and the ideal technique for 
collection of samples especially blood to avoid haemo-
lysis. The MBN clinical laboratories are internationally 
accredited and they are involved in regular internal and 
external quality control checks.
The sponsor of this study (Makerere University) does 
not formally monitor studies to ensure compliance and 
adherence to the standard operating procedures of the 
study protocol. The PI will check each case report form 
on submission for completeness and undertake regular 
interviews with study staff and a sample of the study partic-
ipants to check on the adherence. In addition, the regu-
latory bodies such as the IRB, UNCST and National Drug 
Authority also carry out regular scheduled and unsched-
uled spot checks to monitor adherence of the study to the 
approved protocol.
Table 1 Summary of the study procedures and timelines
Procedure
At admission 
(baseline)
1 hour after onset of study 
drug administration At birth
At 7 days 
postpartum
At 14 days 
postpartum
Assessment of eligibility x
Randomisation x
Data collection for baseline parameters x
Study drug administration x
Questionnaire administration x x x x x
Data collection for primary outcome x x
Data collection for secondary outcome x x x
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Ethics and dissemination
Participant safety
During the study, all the serious adverse events will be 
actively identified and reported to the IRB within 24 hours 
of occurrence. We will adopt and use the School of Medi-
cine Research Ethics Committee reporting form. Only 
qualified health workers will be recruited and trained in 
the protocol to work as research assistants on this trial. 
The independent data monitoring committee will review 
unblinded data when one-third of the participants have 
been enrolled and followed up to completion and report 
to the sponsor of the study. If need arises such as patient 
safety, the study Steering Committee and the IDMC will 
request the independent study biostatistician to unblind 
the treatment allocation for a specific patient or group 
of patients without compromising the allocation conceal-
ment for the rest of the participants.
Dissemination plan
Results will be disseminated to the study participants 
through the local radio stations and local council commu-
nity meeting at the village level. Findings will be shared 
with colleagues and administrators in Mbale Regional 
Referral Hospital/Busitema University Faculty of Health 
Sciences and the Uganda MOH through workshops and 
seminars. To reach the wider scientific community, the 
findings will be published in open access peer-reviewed 
journals and presented at both local and international 
conferences. The datasets will be provided free of charge 
by the primary author on request.
Patient and public involvement
The patients and public were not involved in the design 
and conceptualisation of this study.
dIsCussIon
If the preoperative infusion of sodium bicarbonate is safe 
and effective in reducing maternal and fetal lactatemia 
(acidosis) among patients with OL, then the data from this 
trial will inform the design of future trials that will facili-
tate the inclusion of sodium bicarbonate infusion in the 
standard preoperative care for patients with OL in low-re-
source settings. Its adoption will help to mitigate adverse 
maternal and perinatal outcomes associated with OL as a 
tertiary preventive measure for intrauterine maternal and 
fetal resuscitation. OL is still an important clinical and 
public health problem in low-resource settings because 
of the associated maternal and perinatal morbidity and 
mortality caused by the accompanying electrolyte and 
metabolic changes. Therefore, identifying an effective, 
cheap, safe and readily available acid buffer like sodium 
bicarbonate might offer immense health benefits.
In OL, lactatemia might be a protective mechanism 
to prevent uterine rupture especially in the multiparous 
patients and fetal hypoxia by causing relaxation of the 
myometrium in order to improve fetal placental circula-
tion.10–12 Therefore, reversal of lactic acidosis might result 
in stronger uterine contractions and increase the degree 
of fetal hypoxia or risk of uterine rupture especially if the 
surgical intervention is delayed. Thus, although this study 
will help us to understand whether 50 mmol of bicar-
bonate is effective at reversing lactic acidosis; further 
studies will be required to ascertain its effects on maternal 
and fetal morbidity.
In the body, sodium bicarbonate (NaHCO3) rapidly 
disintegrates into sodium and bicarbonate ions and 
its effects wear off in 60–90 min. It does not cross the 
placenta, it is unknown if NaHCO3 is excreted in breast 
milk and its effects on lactation are unknown. Since we 
are administering a single low-dose preoperatively, we 
believe that it will have no effect on lactation. This will 
need further study in the future even if past studies have 
not reported any adverse effects.20–22
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